文献速递心脑血管急症重症综合管理与镇静镇痛

心脏骤停后使用胶质纤维酸性蛋白进行神经预后判断:系统评价与Meta分析

Neuroprognostication After Cardiac Arrest Using Glial Fibrillary Acidic Protein: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2026-01-15
一句话结论成人心脏骤停自主循环恢复后48-72小时GFAP对不良神经结局的预后准确性更优(AUC 0.84-0.88),但作者认为仍属研究性指标,需前瞻性研究验证并确定标准化截断值。

该系统评价与Meta分析检索了PubMed、Scopus、Web of Science和Google Scholar至2025年6月12日,纳入20项研究(12项进入Meta分析),评估成人心脏骤停ROSC后不同时间点GFAP对不良神经结局的预后准确性。不良神经结局患者GFAP中位数在ROSC后24小时(Δ=138.1 pg/mL)、48小时(Δ=471.1 pg/mL)和72小时(Δ=745.7 pg/mL)均显著更高,汇总AUC随时间改善:24小时0.76、48小时0.84、72小时0.88。限定6个月结局和院外心脏骤停的亚组分析结果一致,质量评估显示适用性担忧低但患者选择与流程/时机存在中等偏倚风险。作者认为GFAP是有潜力的时间依赖性生物标志物,但仍属研究性,需前瞻性研究验证临床效用并确定标准化截断值后方可常规应用。

要点

  • 成人心脏骤停ROSC后48-72小时GFAP预后准确性最佳,汇总AUC在48小时为0.84、72小时为0.88,优于24小时的0.76。
  • 不良神经结局患者GFAP中位数显著高于良好结局者:ROSC后24小时Δ=138.1 pg/mL、48小时Δ=471.1 pg/mL、72小时Δ=745.7 pg/mL。
  • 限定6个月结局和院外心脏骤停的亚组分析结果与总体一致。
  • 质量评估显示适用性担忧低,但患者选择与流程/时机存在中等偏倚风险。
  • 作者认为GFAP仍属研究性生物标志物,需前瞻性研究验证临床效用并确定标准化截断值后方可常规实施。

适用人群与场景

  • 纳入随机对照或观察性研究,对象为成人或儿童院内心脏骤停或院外心脏骤停且达到自主循环恢复(ROSC)者,测量任一生物体液中的GFAP并报告神经结局。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,共纳入20项研究,其中12项进入Meta分析;检索PubMed、Scopus、Web of Science和Google Scholar至2025年6月12日。
  • 不良神经结局患者GFAP中位数在ROSC后24小时(Δ=138.1 pg/mL)、48小时(Δ=471.1 pg/mL)和72小时(Δ=745.7 pg/mL)均显著高于良好神经结局患者。
  • 预后准确性汇总AUC随时间改善:24小时0.76、48小时0.84、72小时0.88。
  • 限定6个月结局和院外心脏骤停的亚组分析显示结果一致。
  • 质量评估显示适用性担忧低,但患者选择与流程/时机存在中等偏倚风险。

证据类型、等级与局限

  • 证据类型为系统评价与Meta分析,采用QUADAS-2工具评估研究质量。
  • 质量评估显示适用性担忧低,但患者选择与流程/时机存在中等偏倚风险。
  • 局限:作者指出需进一步前瞻性研究验证临床效用并确定标准化截断值后方可常规实施。

对床旁实践的改变

  • 作者认为GFAP是有潜力的时间依赖性生物标志物,但仍属研究性,尚不能用于常规神经预后判断。
  • 作者建议需前瞻性研究验证其临床效用并确定标准化截断值后方可常规实施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the prognostic accuracy of glial fibrillary acidic protein (GFAP) levels in predicting poor neurologic outcomes in adult patients after cardiac arrest, across different post-resuscitation timepoints.

DATA SOURCES: PubMed, Scopus, Web of Science, and Google Scholar were systematically searched up to June 12, 2025.

STUDY SELECTION: Eligible studies included randomized controlled or observational studies enrolling adult or pediatric patients with in- or out-of-hospital cardiac arrest who achieved return of spontaneous circulation (ROSC), measured GFAP in any biofluid, and reported neurologic outcomes.

DATA EXTRACTION: Three independent reviewers extracted data on study design, population, arrest characteristics, GFAP sampling methods, outcome definitions, and prognostic performance. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool.

DATA SYNTHESIS: Twenty studies were included in the systematic review; 12 contributed to meta-analyses. Median GFAP levels were significantly higher in patients with poor neurologic outcomes at 24 hours (Δ = 138.1 pg/mL), 48 hours (Δ = 471.1 pg/mL), and 72 hours (Δ = 745.7 pg/mL) post-ROSC. Summary area under the curve values for prognostic accuracy improved over time: 0.76 at 24 hours, 0.84 at 48 hours, and 0.88 at 72 hours. Subgroup analyses limited to 6-month outcomes and out-of-hospital arrests showed consistent results. Quality assessment revealed low applicability concerns but moderate risk of bias in patient selection and flow/timing.

CONCLUSIONS: GFAP demonstrates time-dependent prognostic utility in predicting poor neurologic outcomes after cardiac arrest in adults, with optimal performance at 48-72 hours post-ROSC. These findings support suggest that GFAP shows potential as a time-dependent biomarker but remains investigational. Further prospective studies are needed to validate its clinical utility and to determine standardized cutoff values before routine implementation.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mavrovounis G, Beltsios E, Boutsikos I, et al. Neuroprognostication After Cardiac Arrest Using Glial Fibrillary Acidic Protein: A Systematic Review and Meta-Analysis. Crit Care Med. 2026. PMID: 41537653. doi:10.1097/CCM.0000000000007026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。